Trialspark Revenue and Competitors
Estimated Revenue & Valuation
- Trialspark's estimated annual revenue is currently $29.4M per year.
- Trialspark's estimated revenue per employee is $155,000
- Trialspark's total funding is $156M.
- Trialspark's current valuation is $1B.
Employee Data
- Trialspark has 190 Employees.
- Trialspark grew their employee count by 15% last year.
Trialspark's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP, Portfolio and Program Management | Reveal Email/Phone |
2 | Trial Coordinator | Reveal Email/Phone |
3 | Senior Software Engineer | Reveal Email/Phone |
4 | Marketing Associate, Growth Strategy and Operations | Reveal Email/Phone |
Trialspark Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.6M | 3 | 0% | N/A | N/A |
#2 | N/A | 20 | 43% | N/A | N/A |
#3 | $6.7M | 33 | -6% | N/A | N/A |
#4 | $34.4M | 222 | -1% | N/A | N/A |
#5 | $5.2M | 67 | 0% | $10M | N/A |
#6 | $2M | 13 | 0% | N/A | N/A |
#7 | $7.5M | 37 | 0% | $51.6M | N/A |
#8 | $0.3M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 21 | -16% | $3.3M | N/A |
#10 | $3.6M | 20 | 5% | N/A | N/A |
What Is Trialspark?
Trialspark is a software and technology company that accelerates the discovery of new drugs and medical treatments by reimagining the clinical trial process. Today, clinical trials are incredibly inefficient. A single clinical trial can cost more than 100 million dollars and less than 10% of clinical trials are completed on time. Our mission is to bring life saving treatments to patients faster by addressing these inefficiencies.
keywords:Biotechnology, Healthcare, Pharmaceuticals, Health Care Information Technology, Technology, Clinical Trials, Science
$156M
Total Funding
190
Number of Employees
$29.4M
Revenue (est)
15%
Employee Growth %
$1B
Valuation
N/A
Accelerator
Trialspark News
TrialSpark, a New York-based biotech unicorn, raised USD 156 million in a Series C round led by tech investors Sam Altman and Lachy Groom on 1 October 2021. Investors: Tech investors Sam Altman and Lachy Groom led the latest round of funding with participation from new and existing investors, i ...
TrialSpark, a NYC-based next generation pharma company, raised $156MM in Series C funding. The round was led by Sam Altman and Lachy Groom, with participation from new and existing investors, including Sequoia Capital (Series A lead), Thrive Capital (Series B lead), Casdin Capital, Dragoneer, S ...
NEW YORK, May 26, 2021 /PRNewswire/ -- TrialSpark Inc., a tech-enabled drug development company dedicated to improving the speed, quality, and innovation of clinical trials, announced a collaboration today with global biopharmaceutical company Sanofi. Together, the companies will execute clini ...
TrialSpark, a technology company that works to increase access and integrate trial participation into patients' everyday lives, has teamed up
New York-based tech CRO TrialSpark launched its first clinical trial sites as part of a partnership with Novartis that takes a new direction.
Other Companies in New York
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $34.3M | 190 | -36% | $342.1M |
#2 | $53M | 190 | -3% | N/A |
#3 | $44.3M | 190 | 14% | N/A |
#4 | $39.1M | 190 | -5% | $100.9M |
#5 | $52.3M | 190 | 1% | N/A |